GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in the United States with the establishment of a multi-purpose facility in Marietta, Pennsylvania. The company will invest USD 800 million to develop a state-of-the-art drug substance manufacturing facility and additional drug product manufacturing capabilities, creating over 200 new jobs in the region.
The new facility will include an advanced R&D pilot plant designed to manufacture medicines for clinical trials, enhancing GSK’s research and development capabilities in the area. Furthermore, GSK plans to build a dedicated vaccines drug substance facility at the site, leveraging the company’s innovative MAPS technology for future manufacturing. This expansion follows a series of regulatory submissions and approvals. Construction is set to commence by the end of this year, with the drug substance facility expected to be operational by the end of 2027, followed by the drug product facility by the end of 2028. Since 2017, GSK has invested a total of USD 1.3 billion in the US, demonstrating its commitment to advancing healthcare infrastructure and innovation in the country.- Flcube.com
